Eurofins Genomics US announced on September 19 the opening of its new U.S. oligonucleotide manufacturing facility.
The new 75,000-sq-ft facility in Louisville, KY, will significantly increase the manufacturing capacity of Eurofins Genomics US in meeting the global demand for synthetic DNA and RNA, the company said in a statement. The facility's design provides completely segregated production areas for research use only and good manufacturing practices products, according to the company.
Eurofins noted that the new facility incorporates advanced automation and process controls to enhance three factors that are particularly important for next-generation sequencing (NGS) applications, such as NGS adaptors and capture panels: production efficiency, purity, and traceability. In addition, a substantial investment in new equipment will nearly double the firm's capacity, they said.
